Provided by Tiger Trade Technology Pte. Ltd.

ProMIS Neurosciences Inc

14.51
-0.4000-2.68%
Post-market: 14.510.00000.00%19:51 EDT
Volume:7K
Turnover:104.92K
Market Cap:130.12M
PE:-1.15
High:15.05
Open:15.05
Low:14.41
Close:14.91
52wk High:27.40
52wk Low:6.27
Shares:8.97M
Float Shares:4.39M
Volume Ratio:0.32
T/O Rate:0.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.6200
EPS(LYR):-22.6100
ROE:-172.30%
ROA:-81.06%
PB:2.63
PE(LYR):-0.64

Loading ...

ProMIS Neurosciences shareholders approved 900,000-share increase to 2025 incentive plan

Reuters
·
May 21

ProMIS Neurosciences initiated with a Buy at Brookline

TIPRANKS
·
May 20

MindWalk reports 10 partner-owned antibody programs in active Phase 1-3 trials

Reuters
·
May 18

Analysts’ Top Healthcare Picks: ProMIS Neurosciences (PMN), Evolent Health (EVH)

TIPRANKS
·
May 16

ProMIS Neurosciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

ProMIS Neurosciences Q1 EPS $(1.26) Beats $(1.48) Estimate

Benzinga Earnings
·
May 12

ProMIS Neurosciences Q1 FY26 net loss widens to $8.24 million

Reuters
·
May 12

ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

THOMSON REUTERS
·
May 12

ProMIS Neurosciences Inc expected to post a loss of $1.48 a share - Earnings Preview

Reuters
·
May 08

ProMIS Neurosciences director Patrick D. Kirwin acquires $45,320 common shares

Reuters
·
Apr 24

Fact Check: No, the Whoosh High-Speed Rail Debt Was Not Repaid in Two Months

Tempo
·
Apr 21

ProMIS Neurosciences to present at Bloom Burton Healthcare Investor Conference

Reuters
·
Apr 13

ProMIS Neurosciences Inc expected to post a loss of $1.91 a share - Earnings Preview

Reuters
·
Mar 27

ProMIS Neurosciences Files $200 Million Mixed Shelf

MT Newswires Live
·
Mar 26

ProMIS Neurosciences files $200M mixed securities shelf

TIPRANKS
·
Mar 26

ProMIS Neurosciences Inc - May Offer up to $50 Mln Common Shares Under Sales Agreement - SEC Filing

THOMSON REUTERS
·
Mar 26

ProMIS Neurosciences Q4 EPS $(21.83) Misses $(0.21) Estimate

Benzinga Earnings
·
Mar 25

ProMIS Neurosciences FY2025 net loss rises to $40 million; R&D expenses more than tripled to $33 million

Reuters
·
Mar 25

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

GlobeNewswire
·
Mar 25

ProMIS Neurosciences to present ALS and Parkinson’s data at AD/PD 2026 conference

Reuters
·
Mar 18